Related Experiment Video
Updated: Jul 14, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Hepatitis C virus infection in dialysis patients
Władysław Sułowicz1, Andrzej Radziszewski, Eve Chowaniec
1Department of Nephrology, Medical Faculty, Jagiellonian University, Krakow, Poland. wladsul@mp.pl
Insights
Hepatitis C virus (HCV) infection poses a significant risk to hemodialysis patients, with high prevalence due to inadequate infection control. Current antiviral therapies show limited efficacy and poor tolerance in this population.
Area of Science:
- Hepatology
- Infectious Diseases
- Nephrology
Background:
- Hepatitis C virus (HCV) infection is a global health concern, causing chronic liver disease, cirrhosis, and hepatocellular carcinoma.
- Hemodialysis patients represent a high-risk group for HCV infection, with prevalence varying significantly worldwide.
- Factors contributing to high HCV incidence in dialysis include community prevalence, inadequate infection control, and patient-to-patient transmission.
Purpose of the Study:
- To review the epidemiology and diagnostic approaches for Hepatitis C virus in hemodialysis patients.
- To evaluate the efficacy and tolerability of current antiviral therapies for HCV in this specific patient group.
- To discuss emerging therapeutic strategies for HCV in hemodialysis patients.
Main Methods:
- Review of diagnostic methods for HCV, including antibody detection, HCV RNA quantification, and genotyping.
- Analysis of treatment outcomes for hemodialysis patients receiving interferon-alpha (INF-alpha) based therapies.
- Discussion of the role of ribavirin and pegylated interferon in treatment-experienced patients.
Main Results:
- HCV genotypes 1a and 1b are most prevalent in Europe and Japan, with genotype 1b associated with more severe liver disease.
- Interferon-alpha (INF-alpha) therapy offers marginal benefits in dialysis patients but is poorly tolerated.
- Ribavirin is generally not recommended, but its combination with pegylated interferon is being explored for refractory cases.
Conclusions:
- Hepatitis C virus poses a substantial threat to hemodialysis patients, necessitating stringent infection control measures.
- Current antiviral treatments for HCV in dialysis patients are limited by efficacy and tolerability.
- Further research into optimized and safer therapeutic regimens is crucial for managing HCV in this vulnerable population.
Abstract:
Hepatitis C virus (HCV) infection is a global health problem, common worldwide, leading to acute and chronic hepatitis and its consequences of hepatocirrhosis and hepatocellular carcinoma. Patients on hemodialysis belong to the high-risk group of HCV infection. The prevalence of HCV infection in dialysis patients ranges from 4% to more than 70% in some countries. The main reasons for such a high incidence of infections are a high prevalence of HCV infection in the general population, lack of standard infection precautions and effective vaccination, inadequate disinfection procedures of dialysis machines and other medical equipment, as well as spread of infection from patient to patient, especially in dialytic centers with a high percentage of infected patients. The diagnostic procedures useful in the evaluation of HCV infection are detection of anti-HCV antibodies, identification of HCV RNA, counts of virus copies, and identification of its genome. From the 6 major genotypes and multiple subtypes of the HCV, genotypes 1a and 1b are the most common in Europe and Japan, and 1b is responsible for more severe liver disease and aggressive course leading to liver fibrosis. Antiviral therapy of HCV+ dialysis patients with interferon-alpha (INF-alpha) gives slightly better results than in the general population, but is poorly tolerated and associated with side effects. Although ribavirin in not recommended for dialysis patients, the addition of small doses of this compound to pegylated INF is discussed, especially for patients in whom previous infection treatment failed.
Related Concept Videos
01:25Hepatitis
01:24Hemodialysis II: Procedure and Complications
01:28Viral Hepatitis I: Introduction
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
01:25Hemodialysis I: Introduction
01:27Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...